7th Jun 2016 06:59
LONDON (Alliance News) - ImmuPharma PLC Tuesday said it has commenced dosing its first patients in Europe in its phase III clinical trial of its treatment for lupus, Lupuzor.
Recruitment for this phase III trial will occur in up to 35 sites in Europe and 10 sites in the US.
"This a further key milestone for ImmuPharma's Lupuzor trial with now both the US and European sites dosing Lupus patients. We look forward to providing further positive updates on this Lupuzor Phase III study as it progresses throughout this year and 2017," said Chairman Tim McCarthy in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma